26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Intrauterine adhesions (IUA) are the most common cause of uterine infertility and are caused by endometrium fibrotic regeneration following severe damage to the endometrium. Although current stem cell treatment options using different types of autologous stem cells have exhibited some beneficial outcomes in IUA patients, the reported drawbacks include variable therapeutic efficacies, invasiveness and treatment unavailability. Therefore, the development of new therapeutic stem cell treatments is critical to improving clinical outcomes.

          Methods

          Twenty-six patients who suffered from infertility caused by recurrent IUA were enrolled in this prospective, non-controlled, phase I clinical trial with a 30-month follow-up. During the procedure, 1 × 10 7 umbilical cord-derived mesenchymal stromal cells (UC-MSCs), loaded onto a collagen scaffold, were transplanted into the uterine cavity following an adhesion separation procedure. Medical history, physical examination, endometrial thickness, intrauterine adhesion score and the biological molecules related to endometrial proliferation and differentiation were assessed both before and 3 months after cell therapy.

          Results

          No treatment-related serious adverse events were found. Three months after the operation, the average maximum endometrial thickness in patients increased, and the intrauterine adhesion score decreased compared to those before the treatment. A histological study showed the upregulation of ERα (estrogen receptor α), vimentin, Ki67 and vWF (von Willebrand factor) expression levels and the downregulation of ΔNP63 expression level, which indicates an improvement in endometrial proliferation, differentiation and neovascularization following treatment. DNA short tandem repeat (STR) analysis showed that the regenerated endometrium contained patient DNA only. By the end of the 30-month follow-up period, ten of the 26 patients had become pregnant, and eight of them had delivered live babies with no obvious birth defects and without placental complications, one patient in the third trimester of pregnancy, and one had a spontaneous abortion at 7 weeks.

          Conclusions

          Transplanting clinical-grade UC-MSCs loaded onto a degradable collagen scaffold into the uterine cavity of patients with recurrent IUA following adhesiolysis surgery is a safety and effective therapeutic method.

          Trial registration

          Clinicaltrials.gov. NCT02313415, Registered December 6, 2014.

          Electronic supplementary material

          The online version of this article (10.1186/s13287-018-0904-3) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found
          Is Open Access

          Mesenchymal stem cells in regenerative medicine: Focus on articular cartilage and intervertebral disc regeneration.

          Musculoskeletal disorders represent a major cause of disability and morbidity globally and result in enormous costs for health and social care systems. Development of cell-based therapies is rapidly proliferating in a number of disease areas, including musculoskeletal disorders. Novel biological therapies that can effectively treat joint and spine degeneration are high priorities in regenerative medicine. Mesenchymal stem cells (MSCs) isolated from bone marrow (BM-MSCs), adipose tissue (AD-MSCs) and umbilical cord (UC-MSCs) show considerable promise for use in cartilage and intervertebral disc (IVD) repair. This review article focuses on stem cell-based therapeutics for cartilage and IVD repair in the context of the rising global burden of musculoskeletal disorders. We discuss the biology MSCs and chondroprogenitor cells and specifically focus on umbilical cord/Wharton's jelly derived MSCs and examine their potential for regenerative applications. We also summarize key components of the molecular machinery and signaling pathways responsible for the control of chondrogenesis and explore biomimetic scaffolds and biomaterials for articular cartilage and IVD regeneration. This review explores the exciting opportunities afforded by MSCs and discusses the challenges associated with cartilage and IVD repair and regeneration. There are still many technical challenges associated with isolating, expanding, differentiating, and pre-conditioning MSCs for subsequent implantation into degenerate joints and the spine. However, the prospect of combining biomaterials and cell-based therapies that incorporate chondrocytes, chondroprogenitors and MSCs leads to the optimistic view that interdisciplinary approaches will lead to significant breakthroughs in regenerating musculoskeletal tissues, such as the joint and the spine in the near future.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Asherman syndrome--one century later.

            To provide an update on the current knowledge of Asherman syndrome. Literature review. The worldwide reports of this disease. Patients with Asherman syndrome who presented with amenorrhea or hypomenorrhea, infertility, or recurrent pregnancy loss. Hysteroscopy and hysteroscopic surgery have been the gold standard of diagnosis and treatment respectively for this condition. The etiology, pathology, symptomatology, diagnosis, treatment, and reproductive outcomes were analyzed. This syndrome occurs mainly as a result of trauma to the gravid uterine cavity, which leads to the formation of intrauterine and/or intracervical adhesions. Despite the advances in hysteroscopic surgery, the treatment of moderate to severe Asherman syndrome still presents a challenge. Furthermore, pregnancy after treatment remains high risk with complications including spontaneous abortion, preterm delivery, intrauterine growth restriction, placenta accrete or praevia, or even uterine rupture. The management of moderate to severe disease still poses a challenge, and the prognosis of severe disease remains poor. Close antenatal surveillance and monitoring are necessary for women who conceive after treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients.

              Acute-on-chronic liver failure (ACLF) is a severe, life-threatening complication, and new and efficient therapeutic strategies for liver failure are urgently needed. Mesenchymal stem cell (MSC) transfusions have been shown to reverse fulminant hepatic failure in mice and to improve liver function in patients with end-stage liver diseases. We assessed the safety and initial efficacy of umbilical cord-derived MSC (UC-MSC) transfusions for ACLF patients associated with hepatitis B virus (HBV) infection. A total of 43 ACLF patients were enrolled for this open-labeled and controlled study; 24 patients were treated with UC-MSCs, and 19 patients were treated with saline as controls. UC-MSC therapy was given three times at 4-week intervals. The liver function, adverse events, and survival rates were evaluated during the 48-week or 72-week follow-up period. No significant side effects were observed during the trial. The UC-MSC transfusions significantly increased the survival rates in ACLF patients; reduced the model for end-stage liver disease scores; increased serum albumin, cholinesterase, and prothrombin activity; and increased platelet counts. Serum total bilirubin and alanine aminotransferase levels were significantly decreased after the UC-MSC transfusions. UC-MSC transfusions are safe in the clinic and may serve as a novel therapeutic approach for HBV-associated ACLF patients.
                Bookmark

                Author and article information

                Contributors
                cy19891006@126.com
                stevensunz@163.com
                zhuhui1231@126.com
                zxh3008@126.com
                gt4205@163.com
                yanguijun55@163.com
                jingmei027@126.com
                donghuibai1989@163.com
                juan920846643@163.com
                wangliu@ioz.ac.cn
                zhouqi@ioz.ac.cn
                whylm@hotmail.com
                1763233177@qq.com
                xmljding@163.com
                drxby@163.com
                yzhou@cgl.ucsf.edu
                haojie@ioz.ac.cn
                jwdai@genetics.ac.cn
                yalihu@nju.edu.cn
                Journal
                Stem Cell Res Ther
                Stem Cell Res Ther
                Stem Cell Research & Therapy
                BioMed Central (London )
                1757-6512
                11 July 2018
                11 July 2018
                2018
                : 9
                : 192
                Affiliations
                [1 ]ISNI 0000 0004 1800 1685, GRID grid.428392.6, The Affiliated Drum Tower Hospital of Nanjing University Medical School, ; Nanjing, China
                [2 ]ISNI 0000000119573309, GRID grid.9227.e, Institute of Zoology, , Chinese Academy of Sciences, ; 1 West Beichen Road, Chaoyang district, Beijing, 100101 China
                [3 ]ISNI 0000000119573309, GRID grid.9227.e, Institute of Genetics and Developmental Biology, , Chinese Academy of Sciences, ; 3 Nanyitiao, Zhongguancun, Beijing, 100190 China
                [4 ]ISNI 0000 0001 2297 6811, GRID grid.266102.1, University of California, ; San Francisco, CA USA
                [5 ]ISNI 0000 0004 1800 1685, GRID grid.428392.6, Department of Obstetrics and Gynecology, , Nanjing Drum Tower Hospital and Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, ; 321 Zhongshan Road, Nanjing, China
                Author information
                http://orcid.org/0000-0001-5475-7840
                Article
                904
                10.1186/s13287-018-0904-3
                6042450
                29996892
                e2c0af64-feea-4d7c-aaef-967521dd81f8
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 6 December 2017
                : 14 March 2018
                : 14 May 2018
                Funding
                Funded by: Strategic Priority Research Program of the Chinese Academy of Sciences
                Award ID: XDA01030505
                Funded by: Jiangsu Provincial Key Medical Center
                Award ID: yxzxb2016004
                Funded by: Jiangsu Translational Medicine Program
                Award ID: BE2016612
                Funded by: Jiangsu Biobank of Clinical Resources
                Award ID: BM2015004
                Funded by: Excellent Youth Natural Science Foundation of Jiangsu Province
                Award ID: BK20170051
                Categories
                Research
                Custom metadata
                © The Author(s) 2018

                Molecular medicine
                asherman syndrome,intrauterine adhesions,uterine infertility,uc-mscs,collagen scaffold

                Comments

                Comment on this article